Senseonics Holdings, Inc. (SENS) witnessed an after-hours plunge of 5.76% on Monday, following the release of its fourth quarter and full-year 2024 financial results.
The medical technology company reported a relatively modest increase in revenue for the fourth quarter and full year 2024, with Q4 revenue reaching $8.3 million, up from $8.0 million in Q4 2023, and full-year revenue of $22.5 million, slightly higher than $22.4 million in 2023. However, the company's net losses continued to widen.
For the full year 2024, Senseonics reported a net loss of $78.6 million, or $0.12 per share, a significant increase from the net loss of $60.4 million, or $0.11 per share, in 2023. While the company cited a reduction in gains due to the exchange of outstanding convertible notes and changes in the fair value of derivatives as contributing factors, the widening losses appear to have disappointed investors despite the revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.